Osteosarcoma is the most common primary cancer of bone and one that predominantly affects children and adolescents. Osteoblastic osteosarcoma represents the major subtype of this tumor, with approximately equal representation of fibroblastic and chondroblastic subtypes.
Introduction
Osteosarcoma (OS) is the most common primary tumor of bone, occurring predominantly in the second decade of life. Conventional osteosarcoma presents as three major subtypes based on histological classifications: osteoblastic, fibroblastic and chondroblastic. Of the OS subtypes osteoblastic is the most common (~60%) with fibroblastic and chondroblastic being approximately equally represented [1] . Despite intensive research efforts, outcomes for patients with OS have not significantly improved in the last three decades [2] . Five year survival for patients with localized disease approaches 70% but falls to between 20-30% for patients with recurrent disease or metastasis at diagnosis [2] . Improving outcomes for these patients will require a concerted effort utilizing a number of approaches, of which accurate murine models form a key pillar [3] . In particular the ability to model and test interventions against highly penetrant and reproducible metastatic disease would be of significant advantage.
Murine models of OS generated over past decades have utilized many approaches including radiation exposure and carcinogens [4, 5] . The recent establishment of tractable genetically defined murine models based on the genetics of human disease offers a new means to understand the molecular genetics of OS and provide for further preclinical testing.
Knowledge from the familial OS predisposition syndromes Li-Fraumeni syndrome and hereditary retinoblastoma has been applied to develop models that mirror human OS [6] [7] [8] .
These models have used conditional Cre:lox alleles of p53 (Trp53, Li-Fraumeni syndrome) and Rb (Rb1, hereditary retinoblastoma) and a range of osteoblastic lineage Cre transgenics.
OS arising in these Cre:lox models shares cardinal features with human OS. The tumors resemble conventional human medullary OS, most closely approximating the fibroblastic/undifferentiated form [6, 7] . The development of OS models that encompass the spectrum of clinical OS subtypes (osteoblastic, chondroblastic and fibroblastic) would provide a broad pre-clinical platform to advance proposed therapies in a more precise manner [9] .
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT 4 Rapid improvements in the fidelity of murine models of human cancer have come about through the use of Cre:lox based approaches to elicit temporal and lineage specific gene modulation [7, 10, 11] . Recently developed transgenic, tetracycline (tet)-regulated shRNA based approaches have allowed for inhibition of endogenous gene expression in vivo [12, 13] .
These have demonstrated efficacy in hematopoietic tumors but have not to date been reported in solid tumor models [13, 14] . A direct comparison of Cre:lox and shRNA approaches in modeling solid tumors is yet to be reported. One outstanding question is how comparable the effects of gene knockout are compared to gene knockdown on the tumor phenotype. The knockdown of a tumor suppressor which is highly mutated in human cancer, such as p53, may result in distinct selective pressures that are not apparent when genomic deletion is used.
Here we describe a new OS model that has utilised in vivo lineage restricted shRNA technology to bring about osteoblast specific knockdown of p53. We have also assessed the effects of concomitant deletion of Rb, known to potentiate OS formation in Cre:lox models but not itself act as an initiating event, with shRNA mediated suppression of p53. These mice develop OS, dependent on p53 loss of function, with near 100% penetrance but at longer latency than Cre:lox-based models targeting the same genetic drivers of OS. In contrast to previous models, tumors in this model more often develop in the long bone and are highly metastatic, features similar to human OS. Compared to Cre:lox tumors, which resemble human fibroblastic or undifferentiated OS, shRNA-driven tumors demonstrate a homogenous osteoblastic OS phenotype. As such, conditional deletion and shRNA mediated knockdown are distinctive in vivo tools and are highly complementary in efforts to establish a collection of murine models that reflect the diverse pathology of human solid tumors.
Materials and Methods
Detailed methods can be found in the supplemental section
Animals
p53.1224 transgenic animals were on a C57Bl6 background [13] ; pRb fl/fl animals have been previously described and were on a C57Bl6 background [15] ; Osx-Cre animals have been previously described and were on a C57Bl6 background [16] . Where mentioned the Osx-Cre p53 fl/fl pRb fl/fl line is the same as that previously described except the mice are from a 4 generation C57Bl6 background [7] . Balb/c nu/nu mice were used as recipients for transplant of primary tumor samples and OS cell lines. All experiments were approved by the AEC (St.
Vincent's Hospital, Melbourne).
Kaplan-Meier Survival Analysis and statistical analysis
K-M survival plots were prepared using Prism software. Statistical analysis was done using
Prism software using Mann-Whitney test and where indicated ANOVA with Bonferroni posttest correction.
MicroCT Imaging
Micro-computed tomography (CT) analysis was performed according to standard procedures using Skyscan1076 (x-ray potential 50KVp, Kontich, Belgium) [17] . A full description is provided in the supplemental methods.
Microarray Sample Preparation and Analysis
Raw data files are available from the NCBI GEO browser (GSE38742). A full description is provided in the supplemental methods.
Flow Cytometry
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 6 Primary osteoblasts were isolated from crushed, digested femur/tibia/iliac crest bones.
Hematopoietic cells were filtered out (40m cell strainer) and the remaining bone was digested with collagenase as described [18] . OS cell lines were prepared from early passage (less than passage 5) cultures by trypsinisation. Antibodies are listed in supplemental methods. Flow cytometry was performed on a FACS LSRII Fortessa interfaced with CellQuest software, data was analyzed in FlowJo (TreeStar). Cell sorting was performed on a FACS Aria.
Results

Transgenic knockdown of endogenous gene expression in osteoblastic cells.
To establish the efficacy of transgenic short hairpin RNA (shRNA) in a lineagerestricted manner, we made use of transgenic mice harboring a microRNA-based shRNA targeting murine p53 driven by a tet-regulated TRE promoter [13] . This allele has been extensively characterized and validated to result in an efficient knock-down of both transcript and protein levels of p53 with no reported non specific effects [12, 19, 20] . These TREp53.1224 mice were crossed with Osx-Cre mice (Fig 1A-1B ) [7] . The Osx-Cre transgene expresses a tetracycline transactivator (tTA) and GFP-Cre under the control of the Osx promoter that largely restricts expression to pre-osteoblasts. GFP identifies cells in which the tTA is transcriptionally active, driving expression of both the p53.1224 shRNA and GFP-Cre.
We have not observed expression of GFP outside of the phenotypic osteoblastic lineage nor have we utilized the doxycyline regulatory capacity to modulate the activity of the tTA in these studies.
To assess knockdown of endogenous p53 we isolated primary osteoblastic cells from the Osx-Cre + p53.1224 + or control animals and performed qPCR. The expression of GFP, indicative of active tTA which mediates expression of the p53.1224 shRNA, and the reduction of endogenous p53 levels were tightly related ( Fig 1C, Supp Fig 1) . We observed a greater than 90% reduction in the expression of the endogenous p53 transcript. This demonstrates effective, osteoblastic restricted p53 knockdown in vivo.
Highly penetrant osteosarcoma using shRNA transgenics.
In aiming to generate solid tumors we based our approach on our previous study that generated OS following Osx-Cre mediated deletion of p53 fl/fl and Rb fl/fl alleles in osteoblastic cells [7] . Osx-Cre p53.1224 mice were crossed with pRb fl/fl mice, as this potentiates tumor formation in a p53 dependent manner [7] . As previously reported, loss of Rb alone does not result in OS. We observed tumor formation in the shRNA mice (referred as shRNA OS) with
a mean latency of 409 days, significantly longer than using Cre:lox alleles (referred to as
Cre:lox OS) where median tumor latency was 177 days ( Figure 1D , Supp Table 1 ).
Differences in the presentation of OS between the two approaches were readily apparent. Firstly, a greater proportion of tumors were found on the lower long bones using shRNA (60% shRNA OS vs 29% Cre:lox OS) accompanied by a reduction in OS formation on the mandible/head (Supp Table 1 ). Secondly, 70% of shRNA mice had metastatic disease at autopsy compared to 29% of Cre:lox animals. Metastatic dissemination to the lung and liver was common, mimicking the hematogenous pattern of spread observed in patients with OS (Supp Table 1 ). The anatomical distribution combined with the slower proliferation of the shRNA cells compared to the Cre:lox OS cells may substantially improve the rates of metastatic dissemination as animals survive for a significantly longer period in the shRNA model than the Cre:lox model where tumours on the head necessitate early euthanasia (Supp Figure 7) . We have not observed non osteoblastic lineage sarcomas or hibernoma (brown fat tumor) formation in the shRNA model as has been reported in the Cre:lox mice [6, 7] .
Consistent with our previous data, homozygous deletion of Rb accelerated tumor formation in the Cre:lox model (Supp Fig 2A) . Interestingly, concomitant deletion of Rb in the shRNA model did not significantly accelerate tumor formation albeit in a small cohort size (Supp Fig   2B) . However, it is possible subset analysis per genotype in small cohorts lacked the statistical power to identify subtle effects of concomitant Rb deletion in the shRNA OS model.
It was appreciable that shRNA mediated knockdown was functionally distinct from deletion using Cre:lox based on the survival amongst p53
fl/fl , p53 fl/+ and p53.1224 cohorts that all had Rb +/+ alleles (Supp Fig 2F) . While the knockdown of p53 reduced gene dosage of p53
by a much greater degree than that in the somatic heterozygous state, the shRNA median survival was considerably longer than that of p53 fl/+ animals. Thus, the shRNA mediated knockdown of p53 was functionally distinct from gross deletion of p53 using Cre:lox methods. Collectively these results demonstrate that loss of p53 is the driving genetic lesion leading to initiation of OS irrespective of the means used to reduce p53 expression. we detected a small lesion in the fibula and monitored its in vivo progression by serial imaging ( Figure 2E ).
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Differentiation marker analysis confirm differentiated nature of shRNA OS
To confirm the histological findings, qPCR on whole tumors and cell surface profiling of primary OS cell cultures (< passage 5) was performed. Cell cultures were readily
established from both models by mechanical dissociation and plating. Cultures from shRNA tumors proliferated significantly more slowly than those obtained from Cre:lox tumors (Supp Fig 7) . A range of markers representing stages of osteoblast differentiation was assessed ( Figure 2F ). shRNA OS had the gene expression pattern of a more differentiated cell type than Cre:lox OS ( Figure 2G ). Under in vitro differentiation conditions the shRNA OS cell cultures more rapidly mineralised compared to Cre:lox OS, in keeping with a mature osteoblast (Supp Fig 3) . Furthermore, shRNA OS failed to become adipogenic under inductive conditions, whereas Cre:lox tumors retain adipogenic potential consistent with a pre-osteoblast (Supp Fig 3) . Also in keeping with a more differentiated state, shRNA OS animals had higher serum alkaline phosphatase levels than their Cre:lox counterparts ( Figure   2H ). Therefore the shRNA OS represents a cell population that is osteoblast restricted and is beyond the stage at which it is able to undergo differentiation along the alternate adipogenic lineage.
We next sought to determine the nature and extent of the response of the tumours to stimulation of the parathyroid hormone receptor (PTHR1), prostaglandin receptors and -adrenergic receptors, all critical regulators of osteoblast differentiation. shRNA OS expressed higher levels of the PTHR1 than Cre:lox OS. To functionally assess this we compared the cyclic AMP (cAMP) response of Cre:lox and shRNA OS cell lines to PTH(1-34), prostaglandin E2 (PGE 2 ) and isoproterenol (Iso, Figure 2H ). Cells from both tumors displayed PTH responsiveness, however Cre:lox OS have a ratio of PTH:Iso response of less than 1 consistent with pre-osteoblasts. In contrast, shRNA OS have a PTH:Iso of greater than 2 which is reflective of their mature osteoblastic phenotype and gene expression profile ( Figure 2I, Supp Fig 4) . PGE 2 response was largely comparable between the models.
Collectively these data demonstrate that the fibroblastic and osteoblastic OS subtype models are qualitatively distinct in regards to their differentiation stage.
Early passage cell lines (< passage 5) were assessed for surface expression of Sca-1 and CD51 (Integrin V) [7] . Pre-osteoblastic cells have a phenotype that is hematopoietic (CD45) and endothelial (CD31) marker negative and Sca-1 + CD51 + . As cells mature they become Sca-1 lo/-CD51 lo/+ osteoblasts ( Figure 3A ). Consistent with our previous analysis Cre:lox OS lines are Sca-1 + CD51 + , corresponding to their assignment as pre-osteoblasts [7] ( Figure 3A) . The Osx-Cre transgene (GFP signal) can be detected in a significant proportion of the Sca-1 + population serving as an endogenous transcriptional reporter of the preosteoblastic state ( Figure 3B ). Further analysis using the recently described marker PDGFR (CD140a) demonstrated that the Cre:lox OS cells are predominantly Sca-1 + CD51 + PDGFR + ( Figure 3C ) [21] . The shRNA OS and metastatic lines were predominantly Sca-1 lo/-CD51 lo/+ , the surface expression pattern of mature osteoblasts. The cells were essentially negative for both the Osx-Cre transgene (GFP) and PDGFR. Thus the surface marker profile, qPCR and histological presentation all demonstrated that the OS arising through use of shRNA knockdown of p53 is an osteoblastic OS distinct from the less-differentiated, pre-osteoblastic OS subtype generated using Cre:lox mediated deletion of p53.
Disabling of the endogenous p53 pathway in the absence of hairpin expression
One attractive feature of the transgenic shRNA models is the potential for reversible loss of function [12, 13] . Having demonstrated that p53 knockdown led to OS development (Figure 1 ), we reasoned that reactivation of p53 in established OS would allow assessment of the tumor dependence on p53 suppression. In principle, the Osx-Cre strategy should result in co-expression of GFP and p53 shRNA during OS development as both are controlled by tTAdependent TRE promoters. However, we were surprised to find that shRNA tumors contained very low to negligible levels of GFP, even in the absence of doxycycline ( Figure 3B ). This suggested that either the Osx-Cre promoter was not active in the tumors, that p53 shRNA expression had somehow been uncoupled from GFP reporter expression during OS development, or that the shRNA-driven OS cells had evolved to become independent of p53 knockdown. We have previously observed that there are only low levels of GFP, reflective of expression of the Osx-Cre transgene and tTA, in adult mice and OS cells isolated from
Cre:lox tumors. This is most consistent with the transgene not being robustly expressed throughout osteoblast development but rather in a window of development coinciding with pre-osteoblastic cells. Therefore we assessed the p53 response in primary cell cultures derived from shRNA OS to ascertain the status of the p53 pathway in the tumors.
In Cre:lox OS, which is p53 deficient, there are barely detectable levels of endogenous p53 expression in early passage cell lines, likely arising from minor hematopoietic contaminants (<1% CD45+ve cells; Figure 4A ). There was a 2-log reduction in endogenous p53 expression in shRNA OS lines compared to control (<1% CD45+ve cells; Figure 4A ). However, compared to Cre:lox OS cell lines, shRNA OS lines have a 2-log increase in p53 transcript levels. To assess if the p53 pathway was functional the induction of classical p53 target genes p21 Cip1 and Noxa in response to doxorubicin was determined [22] .
The control primary osteoblasts displayed a robust induction of both p21 We finally assessed if the endogenous p53 allele had undergone methylation-induced silencing [24] . Doxorubicin treatment of the control Kusa4b10 osteoblastic cell line elicited a
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13 strong induction of Noxa expression, which was further enhanced by treatment with the demethylating agent 5-Aza-2'-deoxycytidine (5-AzadC; Figure 4C ). Treatment of shRNA OS cells with 5-AzadC did not affect the expression of the endogenous p53 transcript ( Figure   4C ). Furthermore, treatment with 5-AzadC and doxorubicin failed to induce the expression of Noxa, demonstrating that the p53 pathway in shRNA OS is not functional ( Figure 4C ). These studies demonstrate that the shRNA OS cells have evolved an inactive p53 pathway, thus becoming independent of the continued requirement for the shRNA activity.
Karyotypic complexity with recurrent changes
A hallmark of human OS is karyotypic complexity in the absence of recurrent translocations [25] . We assessed early passage OS cultures derived from the shRNA tumors ( Figure 5A ). All shRNA OS had clonal cytogenetic abnormalities and demonstrated karyotypic complexity. Multiple clonal numerical abnormalities were present in all cases and clonal structural abnormalities detectable at the resolution of metaphase cytogenetics were present in 4/6 tumors. The most frequent changes were recurrent gains of chromosomes 14 and 15 and loss of chromosome 3, 7 and 12, all of which were present in at least 50% of cases. Most striking was recurrent loss of chromosome 7 (n=6/6) ( Figure 5B ). A reassessment of data from the Cre:lox OS also revealed frequent loss of chromosome 7 [7] , suggesting that this may be a common mechanism to generate OS. Chromosomes 6, 8 and 15 were the chromosomes most commonly involved in inter-chromosomal rearrangement ( Figure 5C ).
Chromosome 15 demonstrated a very high rate of collective abnormalities, including copy number gain or structural rearrangement ( Figure 5C ). As is seen with human OS none of the translocations were recurrent. Therefore, independent of the means used to disrupt p53, cells proceed via a common pathway involving loss of chromosome 7 and copy number increase/rearrangement of chromosome 15 during OS development. The non-random, recurrent nature of the abnormalities suggests that shRNA OS tumors share programmed major pathways of tumor initiation and progression.
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Gene expression profiles and comparison to human
To determine if the distinct histology of the fibroblastic and osteoblastic OS models was associated with a specific gene expression pattern we conducted micro-array analysis.
When assessed at a level of 2 fold or greater change in gene expression and a statistical significance level of P<0.05, less than 3% of expressed (273 of 9361) genes were differentially expressed between Cre:lox and shRNA OS respectively ( Figure 6A ). The shRNA OS had increased expression of genes associated with mature osteoblasts such as osteocalcin and DMP1 concordant with our qPCR analysis. Interestingly, there was evidence of differential expression of components of the Wnt pathway between the models. This is consistent with the known roles for this pathway in the regulation of osteoblast differentiation and its altered expression in human OS [26, 27] . There were also changes in the expression of different matrix /cell surface and signaling transcripts.
We next assessed co-ordinate changes in gene expression signatures using the gene set enrichment analysis (GSEA) approach and Ingenuity Pathway Analysis (IPA) [28] . The most significantly enriched signature using GSEA in Cre:lox OS was a gene set associated with acute deletion of the Rb gene ( Figure 6B ). This was unexpected as both groups contained Figure 6B ). The maintenance of a hypoxic state is known to restrain the differentiation of osteoblastic cells and was also observed using IPA ( Figure 6C ) [29] .
IPA analysis also revealed activation of TNF and TGF transcriptional programs in Cre:lox OS ( Figure 6C ). In the shRNA OS there was enrichment of gene sets associated with chromosomal aberrations in a range of human cancers and with cell-cell junctions and adhesion (Supp Fig 5) . Collectively these analyses suggest that there are distinctive gene expression signatures associated with each OS subtype that may contribute to the differentiation stage of the tumors.
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ACCEPTED MANUSCRIPT 15 Next, we compared the shRNA and Cre:lox OS to human sarcomas and other defined murine sarcoma models using the metagene projection methodology [7, 30] . The metagene training set for a subset of human sarcomas was obtained from a dataset of human mesenchymal derived tumors ( Figure 6D ) [31] . We validated the metagene classifiers through addition of test sets obtained from independently derived human sarcoma profiles [32, 33] .
This demonstrated that the metagene approach performed as a robust classifier of sarcoma.
The Cre:lox and shRNA OS samples were then applied as test sets, resulting in a clear association of the current murine OS models with the human OS samples (F7 metagene classifier; Figure 6D ). Murine OS we have previously described (mOS (Cre:lox)) and those derived independently from p53 +/-animals also align with the human OS and Cre:lox and shRNA OS models [34] . Comparison to other murine sarcoma models demonstrated that OS represents a distinct entity from other mesenchymal derived tumors such as genetically engineered synovial sarcoma models [32, 35, 36] . One interesting finding is that irrespective of the means used to modulate p53 in murine models of OS the resulting tumors share a gene expression signature of human OS. These analyses demonstrate the shRNA and Cre:lox models of OS generated are faithful representations of human OS.
Discussion
Collectively the data demonstrate that lineage restricted shRNA against p53 is able to efficiently induce solid tumors, in this iteration osteosarcoma. We propose a model whereby use of Cre:lox alleles of p53 results in acute effect on differentiation and immortalisation of a pre-osteoblastic cell, ultimately leading to a fibroblastic OS ( Figure 7B ). This is consistent with previous reports where loss of p53 leads to an increased expression of both Runx2 and
Osterix and an increase in proliferation [37] . The knockdown of p53 using the shRNA approach would be predicted to result in a less sudden arrest in cell maturation and differentiation, allowing osteoblast differentiation to proceed further prior to immortalization The use of shRNA for tumor modeling has been most widely reported in the hematopoietic system, where high levels of expression can be enforced by retroviral infection approaches and coupling of the tTA/rtTA to the tumor initiating oncogene [14] . Recently several groups have reported application of shRNA to solid tumor modeling with varying efficiency. Inducible knockdown of PDK1 in the whole animal using a Rosa26 knock-in approach was found to have no effect on tumourigenesis dependent on PTEN deficiency [39] .
Knockdown of GATA4 in the whole animal resulted in a range of phenotypes and a 10%
incidence of ovarian teratoma [40] . Our study is distinct from these in that we have demonstrated the efficacy of lineage-restricted knockdown with a high incidence of tumor initiation driven by reductions in p53 levels.
A compelling finding from these studies is that inactivation of the p53 pathway is the driving lesion required to generate experimental OS. The concurrent deletion of Rb can
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17 accelerate OS formation in the absence of p53 but cannot function as an initiating event itself.
This is consistent with a range of other models utilizing either p53 conditional alleles and different menenchymal/osteoblastic Cre lines or transgenic models over-expressing T antigen [5, 8] . It is apparent that the p53.1224 shRNA results in a strong pressure to inactivate the endogenous p53 pathway. This observation may become important with the increase in efforts to silence tumor suppressors using shRNA. Whilst we have been unable to define the nature of the disruption of the p53 pathway, the shRNA OS cells are deficient in the p53
response following exposure to chemotherapy. This is evident from the functional tests and also the microarray comparisons where the core genetic signatures of OS derived by shRNA are largely indistinguishable from that of p53 deficient OS. Our results demonstrated that, at least in this example, the effects of complete loss and knock-down of gene expression are qualitatively different and result in distinctive pathology, similar to that described for Pten [41, 42] . We had previously observed that tumors arising in the Cre:lox model from p53 fl/+ animals evolved with loss of heterozygosity of the retained p53 allele [7] . This result together with the results from the shRNA model would strongly imply that near complete inactivation of the p53 pathway is absolutely required for OS.
Karyotypic analysis of the shRNA OS identified clonal, chromosomal alterations arising during the process of evolution of OS that are recurrent. These included loss of chromosome 7 and a gain or rearrangement of chromosome 15. Chromosome 7 copy number was reduced in both shRNA and Cre:lox OS. Where cells are tetraploid, chromosome 7 is present at a reduced, but never completely absent, copy number. Mouse chromosome 7 is syntenic to regions of human chromosomes 10, 11, 15, 16 and 19 (Ensembl) . Of these, syntenic sections of 10, 11 and 16 are also lost in cases of human OS [43, 44] . Candidate genes of interest on chromosome 7 include the Wnt pathway members DKK3 [45] and Wnt11 
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Ectopic expression of c-Myc was demonstrated to induce OS in vivo and was able to contribute to transformation of mesenchymal progenitors that gave rise to OS on transplantation [47, 48] . Interestingly in both of these cases there was a significant contribution from the inactivation of the "Rb-pathway", as either a co-operative mutation or in modifying the response to Myc reactivation. The region containing c-Myc was also frequently amplified in OS arising in p53 +/-animals [35] . Another gene of interest, linked to the same genomic region as c-Myc, is osteoprotegerin (OPG). OPG is secreted by osteoblasts and acts as a decoy receptor to inhibit bone resorption and is produced by human OS lines [49, 50] . These analyses suggest that pre-osteoblasts/osteoblasts undergo a recurrent path that involves inactivation of both the p53 and Rb pathways, a gain of Myc (Chr 15 gain/rearrangement) and the reduction in gene dosage of chromosome 7.
Through use of a distinct genetic modification technology for perturbing p53 function in osteoblasts we have revealed a new model of a tumor subtype. The contribution of the tTA line cannot be understated. It may be that a more highly active tTA in the osteoblast lineage would result in an disease more comparable to that from Cre:lox approaches. The Osx driven tTA may lend itself to a subtlety of phenotype that is permissive for the generation of the osteoblastic OS. Modeling solid tumors using the approach described may be advantageous in recapitulating the selective pressure placed on critical pathways, such as p53, in human cancers. These results also demonstrate that, at least in the case of p53, genetic deletion using Cre:lox technology and gene knock-down using shRNA are not directly comparable and can elicit distinct pressures during tumor evolution in vivo. As such, the process of initiation and maintenance may more closely resemble the process in human cells, also resulting in an extended latency and increase in metastatic disease.
Conclusion
The variation in any human cancer can only be adequately captured experimentally through the use of more than one murine model. We and others have previously described an OS model where mice present with a phenotype most similar to fibroblastic/undifferentiated OS [6, 7] . We now report a highly penetrant model of osteoblastic OS with a high frequency of metastatic dissemination. The development of this new line provides a valuable new experimental tool and establishes a model of the most common form of clinically managed OS [9] . Through a cross species comparison we demonstrate that both Cre:lox and shRNA OS models are faithful recapitulations of human OS validating these as useful for further preclinical application. shRNA OS is an osteoblastic subtype, in contrast to a predominantly fibroblastic generated using Cre:lox based deletion of p53. 
